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An Estimator Of Intervention Effect On Disease Severity
David Siev
USDA Center for Veterinary Biologics

When a medical intervention prevents a dichotomous outcome, the size of its effect is often estimated
with the prevented fraction. Some interventions may reduce the severity of an outcome without entirely
preventing it. To quantify the effect of a severity-moderating intervention, a measure termed the mitigated
fraction (MF) is proposed. MF has broad applicability, because it measures the overlap of two empirical
distributions based on their stochastic ordering. It is also useful in the specific context of medical
interventions, because it shares certain structural and functional features with the prevented fraction. The
two measures may be applied together in a single semiparametric model with components for outcome
prevention and for severity conditional on the presence of the outcome.
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Introduction

For vaccination, PF is the relative
decrease in the probability a vaccinate will
become a case, while MF is the relative increase
in the probability that a vaccinate’s disease will
be less severe than a nonvaccinate’s disease.
This article shows its origin, describes some of
its features, and illustrates how PF and MF may
be components of a nested model.

When a medical intervention is intended to
prevent a dichotomous outcome, such as the
presence or absence of disease, an estimator
known as the prevented fraction (PF) is
commonly used to measure its effect. Vaccine
efficacy, for example, is often estimated using
some form of prevented fraction. Some
interventions are, however, intended to reduce
disease severity without entirely preventing
disease. It would be valuable to have an
estimator that is broadly applicable for
evaluating vaccine efficacy in reducing disease
severity (Mehrotra, 2004). An estimator that has
proved useful in animal vaccine studies is the
mitigated fraction (MF). The mitigated fraction
is a new incarnation of an old statistic with a
number of salient attributes. It is both analogous
in function and homologous in structure to the
prevented fraction.

Example
A swine respiratory disease vaccine
study included groups of pigs treated with either
vaccine or placebo. All subjects were exposed to
the pathogen and subsequently sacrificed. At
postmortem examination, the extent of gross
lesions in the lungs of each subject was
estimated by visual approximation. Two
observers independently sketched on a grid the
dorsal and ventral surfaces of each of the seven
lung lobes. The fraction of each lobe was taken
as the average of the two surfaces and two
observers. The lobe fractions were weighted (by
their standard relative mass) and summed to
arrive at the fraction of the lungs consisting of
gross lesions. They are shown in Figure 1.
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Figure 1. Fraction of lungs consisting of gross
lesions. Number of subjects – placebo: 21,
vaccine: 22. Points are jitter vertically to aid
visualization.

How then should one analyze and
summarize the findings of this study? The
subjects could be divided into unaffected (0%
lesions) and affected (more than 0% lesions).
The prevented fraction could then be estimated,
using methods for binary data. Important
information is lost, however, if one only
considers whether the response was present or
absent and ignores its severity, particularly
because most subjects were affected, and there
was a wide range of response.
An approach often seen with this type of
data is to calculate the average percent in each
group and compare the group averages by their
difference or relative difference. Taking
averages is not the soundest way to summarize
data that are highly skewed and border a
boundary of the parameter space. The resulting
summary measure also does not illuminate the
vaccine’s impact on individual subjects, as does
PF, which is the relative decrease in the
probability a vaccinate will become a case. A
measure analogous to PF is MF, the relative
increase in the probability that a vaccinate’s
disease will be less severe than a nonvaccinate’s
disease. An interesting question is whether to
estimate MF for the entire set of data, or only for
those affected by challenge. That point will be
considered further when the example is
revisited.
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Mitigated Fraction
Prevented fraction has the general
form PF = 1 − p2 p1 , where, say, p1 is the
expected fraction of nonvaccinates affected by
disease, and p2 is the corresponding expectation
among vaccinates. As the usual estimator of
vaccine effect, PF is often simply termed
vaccine efficacy (VE) in vaccine studies. Besides
binomial expectations, VE may be constructed
from other parameters that are related in some
way to the probability of disease transmission
(see Table 1 of Halloran et al., 1997, for an
overview).
Suppose that all subjects in a vaccine
trial become sick, whether vaccinated or not.
Rather than looking at the effect of vaccination
on the relative probability of contracting the
disease, one might now wish to consider the
effect of vaccination on the relative probability
that the disease is milder. An estimator may be
constructed that is both analogous to PF in
function (summarizing subject probabilities) and
homologous to PF in structure (difference
relative to nonintervention).
To highlight these features, it is called
the mitigated fraction (MF). That is,
MF = 1 − t2 t0 where t2 is the estimated
probability that a vaccinate’s disease is more
severe than that of a nonvaccinate, and t0 is the
probability of greater severity in the absence of
vaccination. MF may range from -1 to 1, unlike
PF, which can take any real value no greater
than 1. The difference in their ranges is related
to the fact that the constituent probabilities in
MF are relative (more or less severe than the
other treatment group), while those in PF are not
(presence or absence of disease). In practice, if a
vaccine does not actually cause disease, both
MF and PF will take values from 0 to 1.
If disease severity can be graded by
some continuous measure or discrete assessment
in a way that results in unambiguous ranks, the
mitigated fraction is estimated by
MF =

{2 W 1

− n 1 (1 + n 1 + n 2 ) } n 1 n 2

where W is the familiar Wilcoxon rank sum
statistic, n is the number of subjects in a group,
and the subscripts are 1 for nonvaccinates and 2
for vaccinates.
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Background
A general problem is how to distinguish
between samples of two populations in some
quantifiable way that avoids all parametric
assumptions. A useful approach is to consider
the stochastic ordering of the two empirical
distributions. Figure 2 illustrates two estimators
that do so,
Ti = P ro b (Y i > Y j ) + 12 P ro b (Y i = Y j ) .
For continuous random variables
Prob(Yi = Yj) = 0, of course, and the second term
is omitted from the figure label for simplicity,
but without loss of generality. If two
distributions are stochastically identical, the
probability that a realization from one of them is
greater or lower than a realization from the other
is one half. Consequently, θ i rescales Ti to range
from –1 to 1, with 0 corresponding to the null
probability, ½.
θi = 2(Ti − 12)
–1

0

1

0

½

1

θ is used when comparing distributions that
have no particular relative ordering. θ i , on the
other hand, is useful when the distributions arise
in a particular setting that establishes an ordered
relationship. For example, population 2 may be
manifesting the effect of a medical intervention
that is being compared to population 1,
representing placebo treatment.
These estimators are generalizations of
known statistics. For example, mean ridits
(Bross, 1958) are Ti, and Somers’ d statistics
(Somers, 1962) are θ i . (Vigderhous (1979)
noted the connection between ridits and Somers’
d). Somers’ d was conceived as a measure of
association between two ordinal variables, in
contrast to ridit analysis, which was designed to
compare the distributions of an ordinal variable
in each of two distinct populations. Here, they
are generalized to encompass data of all types
that are not necessarily categorical and may arise
from independent or correlated distributions.
This general approach has been advocated by
other authors (Wolf & Hogg, 1971).
It is well known that an estimate of T
may be recovered from the Wilcoxon-MannWhitney statistic (Wolf & Hogg, 1971, equation
1). That may be done as follows.

Ti = Prob ( yi > y j )

Figure 2. Because Ti and Tj are complementary
probabilities, summing to one and equidistant
from ½, θ i may be reformulated as

θi

= Ti − T j
= P(Y j < Yi ) − P(Y j > Yi )

In other words, θ i is a measure of the
overlap between the two distributions based on
their stochastic ordering. A general measure of
the overlap of two distributions is simply θ , the
absolute value of either θ i . θ = θi = 2 ( T − 12 ) ,
where
T = sup {Prob( y1 > y2 ), Prob( y1 < y2 )} .

Ti =

Ui
W − ni (ni + 1) 2
= i
ni n j
ni n j

where
Wi = sum of the ranks in group i (the
Wilcoxon rank sum statistic), and Ui =
number of times a yjk precedes a yih (the
Mann-Whitney U statistic), i.e.,

∑∑ H( y
nj

Ui =

ni

jk

, yih ) ,

k =1 h =1

where

Η(a, b) = 1if a < b; 0 if a > b; and 12 if a = b ,
and yih is the response of subject h (h = 1 ...
ni) in group i (i = 1, 2).
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Substituting θ i = 2 (Ti − 1 2 ) gives

θi =

{2 W

i

− n i (1 + n i + n j ) } n i n

j

Stratified Design
To estimate θ from stratified data use
Ti = U ir
nir n jr , where r indexes the strata.

∑ ∑
r

r

For matched pairs, this reduces to a simple
binomial fraction Ti = I( y jr < yir ) R , where

∑
r

R is the number of pairs and I(i) is the indicator
function. In that case, interval estimation can
proceed by familiar methods for binomial
fractions.
Subject Components
MF may be decomposed into the
contribution of individual subjects. The
component for a vaccinated subject j is
2 n1
sj =
H ( y 2 j , y1 k ) − 1 , which is its
n1 k =1

∑

∑

1 n2
s j . MF is thus the
n2 j =1
mean of the individual subject components.

contribution to MF =

Confidence Intervals
Confidence intervals using normal
approximations can be derived from the
asymptotic variance for W or the asymptotic
variance for Somers’ d provided by popular
software packages. Such intervals depend on
assumptions are preferably avoided and may
even contain inadmissable values. An alternative
is to calculate confidence intervals for MF by
one of the bootstrap methods (Efron &
Tibshirani, 1993); this is an area of ongoing
investigation.
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Graphical Representation (Example)
Figure 3 shows the empirical cumulative
distribution function of the difference
distribution, F (Y2 − Y1 ) , obtained from taking all
pairwise differences between the groups in our
example: dij = y2i − y1 j , where i = 1,..., n2 and

j = 1,..., n1 . The arrow leading from the 50%
quantile indicates the median difference (the
Hodges-Lehmann estimator), which gives some
idea of the amount of shift between the two
distributions. The quantile corresponding to a
difference of zero is the probability that a
vaccinate’s disease is less severe than that of a
nonvaccinate (T1). Rescaling the difference
between T1 and the median gives MF, shown in
the right hand y axis. MF is thus a rescaled
quantile of the difference distribution.
In contrast to the median difference,
which is in the original units of measurement on
the abscissa (x axis), MF reflects probabilities on
the ordinate (y axis). In this example, T1 = 0.69
means that 69% of the nonvaccinates are
expected to be more severely affected than the
vaccinates, MF = 2 (T1 − 1 2 ) = 0.39 , (95% bootstrap CI: 0.06 to 0.68). The vaccine benefited an
estimated 39% of the 50% of vaccinates who, in
the absence of vaccination, would have been
more severely affected than nonvaccinates.
Interpretation and application of MF
MF is the increase due to vaccination of
the probability that a vaccinate’s disease will be
less severe than a nonvaccinate’s disease,
relative to the probability that it would have
been less severe had the individual not been
vaccinated. It is important to avoid direct
comparison between PF and MF, which have
somewhat different implications. Many of the
usual estimators of vaccine efficacy are
concerned with the prevention of outcomes that
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Figure 3. Empirical difference distribution showing MF as a rescaled quantile.
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are links in the chain of disease transmission,
such as infection or infectivity, and in this
respect MF is not like them. PF also relies on
explicit case definitions, while MF is intended
for situations where disease severity need only
be clearly graded.
MF is analogous to PF in that it is based
on estimated subject probabilities. Some relative
difference measures that attempt to mimic PF in
formulation may not necessarily have an
analogous implication and should be interpreted
cautiously. For example, a formulation that is
often used to emulate PF is the relative
difference of means ( ( y1 − y2 ) y1 ). This is, at
best, a comparison of population averages rather
than subject distribution. It is rarely appropriate
as the sole assessment of vaccine efficacy when
the outcome is continuous rather than
dichotomous (and it is particularly misleading
when the data may not have arisen from a

location-scale distribution). Although such
estimators may be devised to emulate the
configuration of PF, they fail to capture a
similar meaning, since what is important about
the constituent parameters in PF is not that they
are means but that they are category
probabilities. In this respect, MF is an estimator
that is analogous to PF.
The use of mean based estimators may
also arise from an understandable desire to
quantify the amount of severity reduction.
Unfortunately, such estimators are sensitive to
the form and scale of the response measurement,
which may vary substantially between similar
studies. MF, on the other hand, is invariant to
order-preserving transformations of the data.
The price for such invariance is that MF gives
no information about the magnitude of disease
severity reduction, and a large value of MF may
result from a small but highly probable reduction
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in severity. That is why it is a good idea to
accompany MF with an estimator in the original
units of measurement, such as the empirical
quartiles illustrated in Figure 1.
MF may also be estimated under a range
of parametric assumptions, thereby offering a
common approach to studies of various types.
The example illustrates its most general
application, where there are no assumptions
other than that the data are legitimately ranked.
MF could just as readily be estimated from
ordinal categories or continuous data. With
categorical data, the estimator based on W
corresponds to the ridit estimator. In parametric
analyses, the probabilities are obtained from the
estimated cumulative distribution functions. For
example, the frequency table shows the number
of subjects of a drug trial in categories of
increasing disease severity. (The data are a
subset of those analyzed by Poon (2004).) By
the formula, estimated MF = 0.08 (95%
bootstrap CI: -0.07, 0.23). By Poon’s latent
normal model, estimated MF = 0.10 (95%
profile likelihood CI: -0.11, 0.30). Regardless
how the probabilities are estimated, the meaning
of MF remains the same.

placebo
drug

→

increasing disease severity
2
22 54 29
3
4
23 45 22
2

Conditional MF in Nested Models
Nested Model 1
Consider a model with a component for
the presence or absence of disease and a
component for disease severity among only
those who become sick. Suppose resistance to
the pathogen is dichotomous, while the immune
response to vaccination among those susceptible
to challenge follows some discrete or continuous
distribution. Such a model may be formulated

f ( y) = π

d

[ (1 − π ) f ( y | y > 0 ) ]

1− d

,

where d = I( y = 0) (i.e. d is an indicator taking
the value 1 if y=0 and 0 otherwise) and
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π = E ( d ) , its expectation. The likelihood is then
factored into a Bernoulli likelihood and a
conditionally independent part which contributes
to the total only for responders. This is a nested
model
with
conditionally
independent
components. Since participation in the second
part is conditional on crossing the hurdle of the
first part, this type of nested model is sometimes
termed a hurdle model (Mullahy, 1986).
f ( y | y > 0)
were completely
If
specified, say as a beta density, maximum
likelihood estimation could be used to assess
how the treatment groups differed with respect
to prevention, conditional severity, or both. If
complete specification is not warranted, PF may
be estimated from the first part and MFC , the
conditional mitigated fraction among those
affected, from the second part. To do so, let
pi = 1 − π i
and
Ti C = Ti | yi > 0, y j > 0 .

Then,
PF = 1 − p2 p1 and MFC = 2T1C − 1 .
The conditionally independent nature of
the nested components distinguishes the nested
model from more complex mixture models. For
example, continuous data with many zeros
would, in some cases, be analyzed with a zeroinflated model. In contrast to a nested model, the
nonresponse portion of a zero-inflated model
describes a latent mixture of two populations,
one which may be incapable of response and
another capable of response but with response
zero according to distribution fY ( y ) , leading to
the formulation
f ( y) = {λ + (1 − λ ) fY (0)} [ (1 − λ ) fY ( y | y > 0)]
d

1− d

,

where λ is the population mixture parameter.
An example of a nested model for
categorized data is the well-known continuationratio factorization of the multinomial likelihood
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into conditionally independent binomial
components. It may be parameterized
L(π ) ∝

J

∏δ

yj
j

(1 − δ j )

n − rj

, where, for the jth of

j =1

J categories, y j is the category count, π j is the
category

probability,

rj = ∑ kj =1 yk

cumulative category count, and n = ∑

is
J
j =1

the

y j is the

total.
The

continuation
ratios
are
π k , the probability of being in

δj =π j ∑
category j given not in any previous category.
Continuation-ratio models are useful for
tabulated health events that occur in a natural
sequence. For example, the impact of a pathogen
on reproductive health may be seen by the
presence of normal conception, gestation,
parturition, and neonatal vigor, and a subject’s
inclusion at any stage depends on successfully
passing the previous stage. Continuation-ratio
models may also be applied to ordinal
categories, such as disease severity, if they are
similarly considered to be nested. In some
situations they may offer an alternative to the
more common cumulative probability models.
Suppose disease is categorized as
absent, mild, moderate, and severe, and the
counts for the two groups are arrayed in a 4 x 2
contingency table. MF could be estimated from
the entire table, or separate estimates could be
obtained for PF and MFC. PF would be
estimated from the 2 x 2 table collapsing over
categories 2 through 4, while MFC would be
estimated from the 3 x 2 table that excludes the
first category. A similar rationale could be
applied to ranked data if each rank were thought
to represent a discrete category.
J
k= j

Implications of Nested Model
What are the implications of the nested
model for prevention and conditional severity?
Suppose all nonvaccinates are sick while some
vaccinates are unaffected ( p1 = 1, p2 < 1 ), and
disease severity is reduced among the
vaccinates. MF is then a simple function of its
components: M F = 1 − (1 − M FC )(1 − P F ) .
Otherwise, in most practical situations where the
vaccine both prevents disease ( PF > 0 ) and

reduces its severity among those affected
( MFC > 0 ), the relationship would be
MF < 1 − (1 − MFC )(1 − PF ) . If the vaccine
reduces disease severity among the affected but
has no effect on disease prevention, although
resistant individuals are found among both
nonvaccinates and vaccinates ( p1 = p2 < 1 ), the
inequality reduces to MF < MFC . In both latter
situations, MFC and PF provide illuminating
information and may be examined separately
from MF. On the other hand, in the unlikely but
not impossible case that the vaccine were to
prevent disease but increase severity among
affected vaccinates ( MFC < 0 ), MF could be a
useful summary which balances the benefit of
prevention against the detriment of increased
severity.
Nested Model 2
Nested models may also be constructed
when the first component is at the end, rather
than the beginning, of the disease process. For
example, suppose participation in the evaluation
of disease severity depends on whether or not a
subject survives. The model would then be
f (y) =

[f

( y | x = 0) π

]

x

(1 − π ) 1 − x ,

where each observation consists of the pair
{ y, x} , y is the measurement of disease severity,
and x takes the values 0 if the subject has died
and 1 otherwise.
Implications of Nested Model 2
What are the implications of the nested
model for severity given that a terminal outcome
has not occurred? Suppose a subject dies. Is its
prior disease severity relevant? There are several
possibilities. For example, in an established
clinical model where the severity of gross
lesions predicts a possibly fatal disease, it may
be valid to include the observations of all
subjects, surviving or not, to assess disease
severity. On the other hand, there may be no
clear association between the observation and
disease. Acute death may occur in response to
pathogen challenge without any clinical signs at
all. Retaining the observations of the dead
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subjects when the severity measure is unrelated
to a primary clinical outcome perpetuates an
incoherent clinical model. In such cases, rank
based methods are sometimes applied after
assigning the dead subjects a common value
greater than the maximum value of the surviving
subjects. This approach treats death as simply
the severest manifestation of disease, ignoring
the qualitative difference between death and
survival. A third position is that death is a
critical event, but the prior disease severity of
dead subjects is of no practical interest, leading
us to exclude them from the evaluation of
disease severity, but including all subjects when
considering mortality. Since participation in
disease severity evaluation is conditional on
survival, a nested model may be constructed in
which each observation consists of the pair
{ y, x} , where x indicates whether or not the
subject has died, and y is the measurement of
disease severity (nested model 2).
Example revisited
In the swine vaccine example, an
estimate of the mitigated fraction is
MF = 0.39 (95% bootstrap CI: 0.06 to 0.68).
(The asymptotic approximation is 0.07, 0.71.) A
number of subjects in the study did not succumb
at all to pathogen challenge. Suppose resistance
to the pathogen is dichotomous, while the
immune response to vaccination among those
susceptible to challenge follows some
continuous distribution. The dichotomous
response may be described by PF, and the
continuous response by MFC , the conditional
mitigated fraction among those affected. PF and
MFC would be derived from the conditionally
independent components of a hurdle model
(nested model 1).
The value of nested models is that they
allow simultaneous inference on two
components that are conditionally independent.
In the example, one would estimate PF by
categorizing all observations as disease positive
if the pathological lung fraction is greater than
zero and disease negative otherwise. MFC is then
estimated using only the nonzero observations.
Taking that approach, point and interval
estimates are PF = 0.21 (-0.15, 0.49), and
MFC = 0.42 (0.01, 0.49). Apparently, the study
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is insufficient for conclusive inference on either
one alone.
Conclusion
Although it is easily calculated from the
Wilcoxon statistic, MF is aimed at estimation
rather than hypothesis testing. Consequently, it
helps focus attention on the clinical relevance of
the outcome. Nonparametric tests are sometimes
abused by those who seem to think that avoiding
certain parametric assumptions also eliminates
the need for forethought in study design. Care is
particularly needed when observations are
recorded in the form of derived ratings such as
complex scoring schemes which, unlike simple
grading scales, often do not preserve a clear
correspondence of score with disease severity.
Unless one is confident in the scores' validity
when ranked, the methods shown here should
not be used. Nonparametric analysis will not
salvage a poorly designed scoring scheme.
Estimation requires an outcome that is
quantitatively meaningful as well as clinically
relevant. The study protocol should explicitly
specify the outcome variable and describe how it
will be recorded. Outcome specification should
also aim to highlight the random structure of the
data rather than conceal or ignore it by appeal to
rank based methods.
For this reason, the use of nonparametric
techniques in pivotal confirmatory studies has
been discouraged (e.g. Longford and Nelder,
1999). Critics point out that reliance on
nonparametric methods may simply postpone
the search for a suitable scale of measurement
and clarification of its stochastic nature, which
are prerequisites for planning a study able to
yield informative estimates of the size and
uncertainty
of
relevant
effects.
Full
distributional specification of a germane
response
variable
is
certainly
ideal.
Nevertheless, the basis of MF on ranks gives it
the very qualities that are valuable in certain
types of studies, particularly where a measure
based on subject probabilities is preferable to an
alternative measure formed from averages.
Because the mitigated fraction is
comparable in structure and function to the
prevented fraction, it is a useful method of
estimating the benefit of an intervention that
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reduces disease severity. Like PF, MF evaluates
the intervention’s effect by the probability a
subject will benefit from the intervention. For
this reason, MFC and PF may illuminate
different aspects of the same intervention when
they are components of a nested model, and MF
may be useful in comparisons between studies.
For example, animal vaccine studies typically
entail challenging all subjects with the virulent
pathogen. The response to challenge often varies
in magnitude between studies, and, when the
response is an uncategorized measure of disease
severity, the relative difference between mean
group responses often varies, as well. While it is
difficult to completely standardize the evaluation
of such studies, MF estimates the probability of
a beneficial response to vaccination, offering a
way to assess the degree of vaccine effect at
different times or locations.
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